본문 바로가기
KERD
논문KCI 등재

Staging Models in Bipolar Disorder: A Systematic Review of the Literature

Ather Muneer
대한정신약물학회 (Korean College of Neuropsychopharmacology)|2016.05|Clinical Psychopharmacology and Neuroscience|제14권 제2호|pp. 117-130

2

조회

0

다운로드

14

인용

0

참고문헌

키워드

Bipolar disorderStagingNeuroprogressionAllostatic loadBiomarkers.

초록

Bipolar disorder is manifested as severe dysregulation of mood with recurrent manic and major depressive episodes. It is associated with psychiatric and medical comorbidities, inadequate response to currently available pharmacological agents and a progressively deteriorating course in many patients. The index episode is often depressive in nature, while the first manic or hypomanic episode may occur several years later in the course of the disorder causing delay in diagnosis and use of inappropriate treatment strategies. Staging has been used to great advantage in other branches of medicine like cardiology and oncology. There is growing realization that major mental disorders are fundamentally progressive, with simpler treatment requirements and better prognosis during initial stages of the illness. Defining these conditions into clinically applicable stages not only helps in better understanding the trajectory of a particular disorder, but also assists in management. Patients with a chronic, recalcitrant condition like bipolar disorder are likely to greatly benefit from this approach. If the illness is correctly identified early in its course, proper treatment can be instigated arresting progression to latter phases which are associated with myriad complications in the biopsychosocial realm. With these considerations, a search of the MEDLINE data base was conducted to seek out literature pertaining to staging models in bipolar disorder. A thorough scrutiny of the existing research work revealed that a number of investigators have endeavored to stage define bipolar disorder. This paper outlines staging proposals for bipolar disorder which have the greatest supporting evidence in the literature.

Abstract

Bipolar disorder is manifested as severe dysregulation of mood with recurrent manic and major depressive episodes. It is associated with psychiatric and medical comorbidities, inadequate response to currently available pharmacological agents and a progressively deteriorating course in many patients. The index episode is often depressive in nature, while the first manic or hypomanic episode may occur several years later in the course of the disorder causing delay in diagnosis and use of inappropriate treatment strategies. Staging has been used to great advantage in other branches of medicine like cardiology and oncology. There is growing realization that major mental disorders are fundamentally progressive, with simpler treatment requirements and better prognosis during initial stages of the illness. Defining these conditions into clinically applicable stages not only helps in better understanding the trajectory of a particular disorder, but also assists in management. Patients with a chronic, recalcitrant condition like bipolar disorder are likely to greatly benefit from this approach. If the illness is correctly identified early in its course, proper treatment can be instigated arresting progression to latter phases which are associated with myriad complications in the biopsychosocial realm. With these considerations, a search of the MEDLINE data base was conducted to seek out literature pertaining to staging models in bipolar disorder. A thorough scrutiny of the existing research work revealed that a number of investigators have endeavored to stage define bipolar disorder. This paper outlines staging proposals for bipolar disorder which have the greatest supporting evidence in the literature.

참고문헌 (88)

  1. Gonzalez R, "The relationship between bipolar disorder and biological rhythms", J Clin Psychiatry, 75, pp.e323~e331 (2014)
  2. Nivoli AM, "Bipolar disorder in the elderly: a cohort study comparing older and younger patients", Acta Psychiatr Scand, 130, pp.364~373 (2014)
  3. Fagiolini A, "Prevalence, chronicity, burden and borders of bipolar disorder", J Affect Disord, 148, pp.161~169 (2013)
  4. Knežević V, "Influence of misdiagnosis on the course of bipolar disorder", Eur Rev Med Pharmacol Sci, 17, pp.1542~1545 (2013)
  5. Leboyer M, "Bipolar disorder: new perspectives in health care and prevention", J Clin Psychiatry, 71, pp.1689~1695 (2010)
  6. Barbosa IG, "Cytokines in bipolar disorder: paving the way for neuroprogression", Neural Plast, 2014, pp.360481~ (2014)
  7. Conus P, "Public health significance of bipolar disorder: implications for early intervention and prevention", Bipolar Disord, 16, pp.548~556 (2014)
  8. Frank E, "All the world's a (clinical) stage: rethinking bipolar disorder from a longitudinal perspective", Mol Psychiatry, 20, pp.23~31 (2015)
  9. Kapczinski F, "Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report", Acta Psychiatr Scand, 130, pp.354~363 (2014)
  10. Duffy A, "How does a developmental perspective inform us about the early Natural History of Bipolar Disorder?", J Can Acad Child Adolesc Psychiatry, 22, pp.6~12 (2013)
  11. Zivanovic O, "Kraepelin's concept of manic-depressive insanity: one hundred years later", J Affect Disord, 137, pp.15~24 (2012)
  12. McGorry P, "Biomarkers and clinical staging in psychiatry", World Psychiatry, 13, pp.211~223 (2014)
  13. Berk M, "Evidence and implications for early intervention in bipolar disorder", J Ment Health, 19, pp.113~126 (2010)
  14. Rybakowski JK, "Response to lithium in bipolar disorder:clinical and genetic findings", ACS Chem Neurosci, 5, pp.413~421 (2014)
  15. Rybakowski JK, "Factors associated with lithium efficacy in bipolar disorder", Harv Rev Psychiatry, 22, pp.353~357 (2014)
  16. Duffy A, "The early natural history of bipolar disorder: what we have learned from longitudinal high-risk research", Can J Psychiatry, 55, pp.477~485 (2010)
  17. Grof P, "Sixty years of lithium responders", Neuropsychobiology, 62, pp.8~16 (2010)
  18. Grof P, "Lithium response across generations", Acta Psychiatr Scand, 120, pp.378~385 (2009)
  19. Garnham J, "Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study", J Affect Disord, 104, pp.185~190 (2007)
  20. Duffy A, "A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment", J Clin Psychiatry, 63, pp.1171~1178 (2002)
  21. Alda M, "The phenotypic spectra of bipolar disorder", Eur Neuropsychopharmacol, 14(Suppl 2), pp.S94~S99 (2004)
  22. Duffy A, "The developmental trajectory of bipolar disorder", Br J Psychiatry, 204, pp.122~128 (2014)
  23. Duffy A, "Early course of bipolar disorder in high-risk offspring: prospective study", Br J Psychiatry, 195, pp.457~458 (2009)
  24. Goldstein BI, "Clinical, demographic, and familial correlates of bipolar spectrum disorders among offspring of parents with bipolar disorder", J Am Acad Child Adolesc Psychiatry, 49, pp.388~396 (2010)
  25. Levy B, "Functional outcome in bipolar disorder:the big picture", Depress Res Treat, 2012, pp.949248~ (2012)
  26. Berk M, "Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors", Neurosci Biobehav Rev, 35, pp.804~817 (2011)
  27. Mesman E, "The Dutch bipolar offspring study: 12-year follow-up", Am J Psychiatry, 170, pp.542~549 (2013)
  28. Sparks GM, "Disruptive mood dysregulation disorder and chronic irritability in youth at familial risk for bipolar disorder", J Am Acad Child Adolesc Psychiatry, 53, pp.408~416 (2014)
  29. Masi G, "Developmental pathways for different subtypes of earlyonset bipolarity in youths", J Clin Psychiatry, 73, pp.1335~1341 (2012)
  30. Singh MK, "Distinguishing bipolar disorder from other psychiatric disorders in children", Curr Psychiatry Rep, 16, pp.516~ (2014)
  31. McNamara RK, "Preventative strategies for early-onset bipolar disorder:towards a clinical staging model", CNS Drugs, 24, pp.983~996 (2010)
  32. Duffy A, "The early manifestations of bipolar disorder: a longitudinal prospective study of the offspring of bipolar parents", Bipolar Disord, 9, pp.828~838 (2007)
  33. Duffy A, "A consecutive series of treated affected offspring of parents with bipolar disorder:is response associated with the clinical profile?", Can J Psychiatry, 52, pp.369~376 (2007)
  34. Faedda GL, "Precursors of bipolar disorders: a systematic literature review of prospective studies", J Clin Psychiatry, 76, pp.614~624 (2015)
  35. Duffy A, "Toward a comprehensive clinical staging model for bipolar disorder: integrating the evidence", Can J Psychiatry, 59, pp.659~666 (2014)
  36. Valentí M, "Risk factors for rapid cycling in bipolar disorder", Bipolar Disord, 17, pp.549~559 (2015)
  37. Tidemalm D, "Attempted suicide in bipolar disorder: risk factors in a cohort of 6086 patients", PLoS One, 9, pp.e94097~ (2014)
  38. 김문두, "The Relationship between Cognitive Decline and Psychopathology in Patients with Schizophrenia and Bipolar Disorder", Clinical Psychopharmacology and Neuroscience, 13(1), pp.103~108 (2015), 대한정신약물학회
  39. Gama CS, "Staging and neuroprogression in bipolar disorder: a systematic review of the literature", Rev Bras Psiquiatr, 35, pp.70~74 (2013)
  40. Fries GR, "Staging and neuroprogression in bipolar disorder", Curr Psychiatry Rep, 14, pp.667~675 (2012)
  41. Bizik G, "Allostatic load as a tool for monitoring physiological dysregulations and comorbidities in patients with severe mental illnesses", Harv Rev Psychiatry, 21, pp.296~313 (2013)
  42. Grande I, "Mediators of allostasis and systemic toxicity in bipolar disorder", Physiol Behav, 106, pp.46~50 (2012)
  43. Kapczinski F, "Allostatic load in bipolar disorder:implications for pathophysiology and treatment", Neurosci Biobehav Rev, 32, pp.675~692 (2008)
  44. McEwen BS, "Protective and damaging effects of stress mediators: central role of the brain", Dialogues Clin Neurosci, 8, pp.367~381 (2006)
  45. Strakowski SM, "Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder", Am J Psychiatry, 159, pp.1841~1847 (2002)
  46. Moorhead TW, "Progressive gray matter loss in patients with bipolar disorder", Biol Psychiatry, 62, pp.894~900 (2007)
  47. López-Larson MP, "Regional prefrontal gray and white matter abnormalities in bipolar disorder", Biol Psychiatry, 52, pp.93~100 (2002)
  48. Kempton MJ, "Meta-analysis, database, and meta-regression of 98structural imaging studies in bipolar disorder", Arch Gen Psychiatry, 65, pp.1017~1032 (2008)
  49. Gulseren S, "T2hyperintensities in bipolar patients and their healthy siblings", Arch Med Res, 37, pp.79~85 (2006)
  50. Fernandes BS, "Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis", J Psychiatr Res, 45, pp.995~1004 (2011)
  51. Lin PY, "State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study", Neurosci Lett, 466, pp.139~143 (2009)
  52. Fernandes BS, "Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis", J Psychiatr Res, 43, pp.1200~1204 (2009)
  53. Iria Grande, "The Role of BDNF as a Mediator of Neuroplasticity in Bipolar Disorder", PSYCHIATRY INVESTIGATION, 7(4), pp.243~250 (2010), 대한신경정신의학회
  54. Kapczinski F, "The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers", Acta Neuropsychiatr, 21, pp.272~274 (2009)
  55. Tramontina JF, "Brain-derived neurotrophic factor serum levels before and after treatment for acute mania", Neurosci Lett, 452, pp.111~113 (2009)
  56. Pfaffenseller B, "Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder", Expert Rev Neurother, 13, pp.827~842 (2013)
  57. Chitty KM, "A longitudinal proton magnetic resonance spectroscopy study investigating oxidative stress as a result of alcohol and tobacco use in youth with bipolar disorder", J Affect Disord, 175, pp.481~487 (2015)
  58. Teixeira AL, "Novel biomarkers for bipolar disorder", Expert Opin Med Diagn, 7, pp.147~159 (2013)
  59. Andreazza AC, "Oxidative stress markers in bipolar disorder: a meta-analysis", J Affect Disord, 111, pp.135~144 (2008)
  60. Andreazza AC, "Serum S100B and antioxidant enzymes in bipolar patients", J Psychiatr Res, 41, pp.523~529 (2007)
  61. Savas HA, "Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes", World J Biol Psychiatry, 7, pp.51~55 (2006)
  62. Andreazza AC, "3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder", J Psychiatry Neurosci, 34, pp.263~271 (2009)
  63. Andreazza AC, "DNA damage in bipolar disorder", Psychiatry Res, 153, pp.27~32 (2007)
  64. Elvsåshagen T, "The load of short telomeres is increased and associated with lifetime number of depressive episodes in bipolar II disorder", J Affect Disord, 135, pp.43~50 (2011)
  65. Saretzki G, "Replicative aging, telomeres, and oxidative stress", Ann N Y Acad Sci, 959, pp.24~29 (2002)
  66. Simon NM, "Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging", Biol Psychiatry, 60, pp.432~435 (2006)
  67. Magalhães PV, "N-acetylcysteine for major depressive episodes in bipolar disorder", Rev Bras Psiquiatr, 33, pp.374~378 (2011)
  68. Khairova R, "Effects of lithium on oxidative stress parameters in healthy subjects", Mol Med Rep, 5, pp.680~682 (2012)
  69. Kapczinski F, "A systemic toxicity index developed to assess peripheral changes in mood episodes", Mol Psychiatry, 15, pp.784~786 (2010)
  70. Brietzke E, "TNF-alpha as a molecular target in bipolar disorder", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.1355~1361 (2008)
  71. Kim YK, "Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder", J Affect Disord, 104, pp.91~95 (2007)
  72. Leboyer M, "Can bipolar disorder be viewed as a multi-system inflammatory disease?", J Affect Disord, 141, pp.1~10 (2012)
  73. Hamdani N, "Immunity, inflammation, and bipolar disorder: diagnostic and therapeutic implications", Curr Psychiatry Rep, 15, pp.387~ (2013)
  74. Kauer-Sant'Anna M, "Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. latestage bipolar disorder", Int J Neuropsychopharmacol, 12, pp.447~458 (2009)
  75. Dickerson F, "Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.952~955 (2007)
  76. Drake C, "Brain inflammation is induced by comorbidities and risk factors for stroke", Brain Behav Immun, 25, pp.1113~1122 (2011)
  77. Evans-Lacko SE, "Medical comorbidity among youth diagnosed with bipolar disorder in the United States", J Clin Psychiatry, 70, pp.1461~1466 (2009)
  78. Goldstein BI, "Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature", J Clin Psychiatry, 70, pp.1078~1090 (2009)
  79. Berk M, "The potential utility of a staging model as a course specifier: a bipolar disorder perspective", J Affect Disord, 100, pp.279~281 (2007)
  80. Kapczinski F, "Clinical implications of a staging model for bipolar disorders", Expert Rev Neurother, 9, pp.957~966 (2009)
  81. Berk M, "Stage managing bipolar disorder", Bipolar Disord, 16, pp.471~477 (2014)
  82. Berk M, "Early intervention in bipolar disorders:clinical, biochemical and neuroimaging imperatives", J Affect Disord, 114, pp.1~13 (2009)
  83. McIntyre RS, "The prevalence and illness characteristics of DSM-5-defined "mixed feature specifier"in adults with major depressive disorder and bipolar disorder:Results from the International Mood Disorders Collaborative Project", J Affect Disord, 172C, pp.259~264 (2014)
  84. Benazzi F, "The continuum", spectrum concept of mood disorders:is mixed depression the basic link?, 2006, pp.256, 512~515
  85. Musselman D, "The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: preliminary findings", Neuropsychopharmacology, 38, pp.1921~1928 (2013)
  86. Raison CL, "A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatmentresistant depression: the role of baseline inflammatory biomarkers", JAMA Psychiatry, 70, pp.31~41 (2013)
  87. Moylan S, "The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications", Mol Psychiatry, 18, pp.595~606 (2013)
  88. Ferensztajn E, "Staging of unipolar affective illness", Psychiatr Pol, 48, pp.1127~1141 (2014)

관련 논문AI추천

The Staging of Major Mood Disorders: Clinical and Neurobiological CorrelatesAther Muneer, Rana Mazommil대한신경정신의학회 · PSYCHIATRY INVESTIGATION2018 · 제15권 제8호Polarity of the First Episode and Time to Diagnosis of Bipolar I Disorder김정현, 장재승, 차보석, 하규섭, 하태현대한신경정신의학회 · PSYCHIATRY INVESTIGATION2009 · 제6권 제2호Bipolar Disorder: Role of Inflammation and the Development of Disease BiomarkersAther Muneer대한신경정신의학회 · PSYCHIATRY INVESTIGATION2016 · 제13권 제1호Pharmacotherapy of Bipolar Disorder with Quetiapine: A Recent Literature Review and an UpdateAther Muneer대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2015 · 제13권 제1호Neuromolecular Etiology of Bipolar Disorder: Possible Therapeutic Targets of Mood Stabilizers박성우, 박원명, 이정구, Dae-Hyun Seog, Mi Kyoung Seo, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2022 · 제20권 제2호Defining “High Recurrence” of Depressive Episodes for Predicting Diagnostic Conversion from Major Depressive Disorder to Bipolar Disorder: A 5-year Retrospective StudyJonghun Lee, Won Joon Choi, Won-Myong Bahk, Won-Seok Choi, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2024 · 제22권 제2호

이 간행물의 다른 논문 (14건)

The Microbiome and Mental Health: Looking Back, Moving Forward with Lessons from Allergic DiseasesSusan L. Prescott, Jeffrey M. Craig, Felice N. Jacka, Alan C. Loganpp. 131-147The Ratio of 2nd to 4th Digit Length in Korean Alcohol-dependent Patients한창우, 원성두, 김대진, 이유상, Hwallip Baepp. 148-152Adjunctive Low-frequency Repetitive Transcranial Magnetic Stimulation over the Right Dorsolateral Prefrontal Cortex in Patients with Treatment-resistant Obsessive-compulsive Disorder: A Randomized Controlled Trial채정호, 이창욱, 정영은, 서호준, 임현국, 엄유현pp. 153-160Early Improvement in One Week Predicts the Treatment Response to Escitalopram in Patients with Social Anxiety Disorder: A Preliminary Study하주원, 신동원, 임세원, 신영철, 신은숙, 오강섭pp. 161-167Heart Rate Variability and the Efficacy of Biofeedback in Heroin Users with Depressive SymptomsJiun-Min Ko, Cheng-Fang Yen, Sheng-Yu Fan, I-Mei Linpp. 168-176
원문 보기